Drug Profile
Research programme: anti-glaucoma therapeutics - EyePoint Pharmaceuticals/Undisclosed company
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator pSivida; Undisclosed
- Developer EyePoint Pharmaceuticals; Undisclosed Company
- Class Antiglaucomas; Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma